glp-1 receptor agonist type 1 diabetes randomized trial Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide Agonists: A Scoping Review SGLT2i and GLP-1 RA therapy

Vanhoutte F, Liang S, Ruddy M, Zhao A, Drewery T, Wang Y, et al

He now specializes in evidence-based weight management, including GLP-1/GIP therapies (semaglutide & tirzepatide)

The pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit

Notably, semaglutide emerged as the second best-selling drug in 2024, and in the same year, sales of tirzepatide increased 124% from the previous year [2]

In fact, by continuously depriving the liver of esterified fatty acids and inhibiting the hepatic glycolytic pathway, glucagon promotes the production of ketone bodies [4143] Hepatic ketogenesis is boosted as a result, and mitochondrial fatty acid oxidation is improved [14, 43]